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Abstract Mediator-associated kinases CDK8/19 are context-dependent drivers or suppressors
of tumorigenesis. Their inhibition is predicted to have pleiotropic effects, but it is unclear whether
this will impact on the clinical utility of CDK8/19 inhibitors. We discovered two series of potent
chemical probes with high selectivity for CDK8/19. Despite pharmacodynamic evidence for robust
on-target activity, the compounds exhibited modest, though significant, efficacy against human
tumor lines and patient-derived xenografts. Altered gene expression was consistent with CDK8/19
inhibition, including profiles associated with super-enhancers, immune and inflammatory responses
and stem cell function. In a mouse model expressing oncogenic beta-catenin, treatment shifted
cells within hyperplastic intestinal crypts from a stem cell to a transit amplifying phenotype. In two
species, neither probe was tolerated at therapeutically-relevant exposures. The complex nature of
the toxicity observed with two structurally-differentiated chemical series is consistent with on-
target effects posing significant challenges to the clinical development of CDK8/19 inhibitors.
DOI: 10.7554/eLife.20722.001
Introduction
The Mediator complex is a multi-subunit regulator of transcription in eukaryotes that transfers sig-
nals from DNA-bound transcription factors to the RNA polymerase II pre-initiation complex
(Allen and Taatjes, 2015; Yin and Wang, 2014; Poss et al., 2013). It also has a role in transcription
elongation and pausing, and can influence chromatin structure, where it facilitates the formation of
enhancer-promoter gene loops and is enriched at ‘super-enhancer’ regions (Allen and Taatjes,
2015; Poss et al., 2013; Whyte, 2013). Mediator activity is regulated by the association with a four-
subunit kinase module containing cyclin-dependent kinase 8 (CDK8), cyclin C (CCNC) and Mediator
subunits MED12 and MED13 (Allen and Taatjes, 2015; Poss et al., 2013; Taatjes et al., 2002). As a
kinase that reversibly associates with the Mediator, CDK8 is thought to regulate gene expression
through phosphorylation of transcription factors and Mediator subunits (Rzymski et al., 2015).
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Phosphorylation by CDK8 can directly alter transcription factor activity (Bancerek et al., 2013;
Morris et al., 2008; Zhao et al., 2013) or mark factors for degradation (Fryer et al., 2004;
Alarco´n et al., 2009; Zhao et al., 2012; Li et al., 2014). The role of CDK8, and the Mediator kinase
module, in the control of transcription may not be unique as paralogs of CDK8, MED12 and MED13
have been identified that may have distinct roles in vitro and in vivo (Sato et al., 2004;
Tsutsui et al., 2008; Galbraith et al., 2013; Westerling et al., 2007).
The biological function of CDK8 varies by cell type and response to different stimuli (Allen and
Taatjes, 2015; McCleland et al., 2015). This is particularly true in cancer, where CDK8 may function
not only as an oncogene, but also as a tumor-suppressor depending on the cellular context
(McCleland et al., 2015; Mitra et al., 2006; Chattopadhyay et al., 2010; Gu et al., 2013;
Firestein et al., 2008, 2010; Seo et al., 2010; Adler et al., 2012). CDK8 may act as an oncogene in
colorectal cancer where CDK8 is amplified, with copy number gains observed in ~60% of tumors
(Firestein et al., 2010; Seo et al., 2010), and shRNA knockdown can reduce the growth of human
colorectal cancer xenografts harbouring CDK8 gene amplification (Firestein et al., 2008;
Adler et al., 2012; Starr et al., 2009). Furthermore, CDK8 expression is reportedly required for
growth of colorectal cancer xenografts and to maintain embryonic stem cells in an undifferentiated
state (Adler et al., 2012). Importantly, CDK8 expression transforms fibroblasts into a malignant phe-
notype, whereas expression of a kinase-dead mutant does not (Firestein et al., 2008). An shRNA
screen has also demonstrated a requirement for CDK8 in the activation of WNT signaling in
eLife digest Healthy cells in the human body can become cancerous if they gain genetic
mutations that allow them to rapidly grow and divide. Some types of cancer respond better to drug
treatments than others and tumors often develop resistance to a particular drug treatment after a
while. Because of this, researchers are always searching for new molecules to develop into
anticancer drugs.
Recently, a team of researchers identified some small molecules that could inactivate two closely
related proteins called CDK8 and CDK19. CDK8 is essential for the WNT signaling pathway – which
enables cells to communicate with one another – and has been extensively studied in various
cancers. Previous studies indicate that this protein can either promote or inhibit the growth of
tumors, depending on the type and stage of the cancer. Furthermore, CDK8 regulates a type of
molecular switch called a “super-enhancer”, which controls the activity of many genes. In contrast,
the role of CDK19 in cells was not as well understood. Here Clarke, Ortiz-Ruiz et al. investigated
whether two different classes of small molecules that target CDK8 and CDK19 (referred to as
“prototype CDK8/19 drugs”) could inhibit the growth of cancers, and whether they have any
harmful side effects on healthy cells.
For the experiments, human cancer cells were implanted into mice. Treating these mice with
prototype CDK8/19 drugs inhibited the activity of CDK8 and CDK19 in the cancer cells and slowed
the growth of colorectal tumors. A type of blood cancer called acute myeloid leukaemia was
particularly sensitive to the drugs. However, Clarke, Ortiz-Ruiz et al. also observed that the
prototype drugs altered the activity of many genes with roles in healthy tissues such as immune,
bone and stem cells. Further experiments in mice and cells grown in the laboratory confirmed that
these prototype drugs have adverse effects on healthy intestinal and bone marrow stem cells and
trigger changes to immune cells. These concerning side effects were also evident when the
prototype drugs were tested in rats and dogs. Furthermore, the experiments indicate that there is
not a suitable range of doses of these drugs in which the therapeutic benefits outweigh the toxic
side effects.
Clarke, Ortiz-Ruiz et al. conclude that the clinical development of CDK8/19 drugs will be
extremely challenging and that their prototype drugs would not currently be suitable for use as
cancer treatments. However, the small molecules they describe will be important probes in research
to study exactly how CDK8/19 regulate gene activity in both healthy cells and cancers.
DOI: 10.7554/eLife.20722.002
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colorectal cancer (Firestein et al., 2008), suggesting that CDK8 and the Mediator kinase module
may promote oncogenesis through activation of the canonical WNT pathway.
Previously, we reported the discovery and optimization of a potent and selective 3,4,5-trisubsti-
tuted pyridine series of small-molecule inhibitors of WNT signaling from a cell-based pathway
screen, and using a chemo-proteomic strategy we identified CDK8 and CDK19 as the primary molec-
ular targets (Dale et al., 2015; Boyer, 2015). Through further optimization we identified a potent,
highly selective and orally bioavailable dual CDK8/19 ligand with excellent cell-based activity and
pharmaceutical properties (Mallinger et al., 2016a). Subsequently, we discovered a second, chemi-
cally-distinct series of CDK8/19 ligands and optimization of pharmacological, pharmaceutical and
pharmacokinetic properties identified a 3-methyl-1H-pyrazolo[3,4-b]pyridine, which also binds to
CDK8/CCNC (Czodrowski et al., 2016). With potent and selective exemplar compounds from these
two structurally differentiated chemical series in hand together with corresponding inactive control
compounds, we were well positioned to investigate the therapeutic potential of dual CDK8/19 mod-
ulation. Specifically, we set out to establish if these compounds had antiproliferative or antitumor
activity and whether a therapeutic window could be identified in preclinical models that would justify
the clinical development of these compounds.
Results
Characterisation of structurally differentiated CDK8/19 ligands
We identified two structurally differentiated, potent, selective and cell permeable chemical series,
namely 3,4,5-trisubstituted pyridines and 3-methyl-1H-pyrazolo[3,4-b]pyridines, suitable for explor-
ing the function of the Mediator complex-associated protein kinases CDK8 and CDK19
(Figure 1A and Figure 1—source data 1). In addition to two tool compounds, 1 (CCT251545;
Mallinger et al., 2015) and 2 (compound 42;Mallinger et al., 2016a), that fulfill all of the criteria set
out for chemical probes (Frye, 2010), the lead compounds from each of the chemical series, 3
(CCT251921; Mallinger et al., 2016a) and 4 (MSC2530818; Czodrowski et al., 2016) had optimal
pharmacological and pharmaceutical properties that made them suitable for further progression to
preclinical studies (Figure 1A and Figure 1—source data 1). All four compounds had single digit
nanomolar binding affinities for CDK8 and 19, and were very highly selective with little evidence for
off-target activity in extended protein kinase panels (Figure 1—source data 1). Our compounds
also potently inhibited inducible (7dF3; Ewan et al., 2010) or basal (LS174T; Dale et al., 2015;
Mallinger et al., 2015) WNT-pathway luciferase-reporter expression together with STAT1SER727
phosphorylation a target-engagement biomarker at low nanomolar concentrations (Figure 1A and
Figure 1—source data 1) (Bancerek et al., 2013; Dale et al., 2015).
A comparison of the co-crystal structure of CDK8/CCNC with 3 or 4 showed that both molecules
adopt a Type I binding mode and make similar contacts with active site residues (Figure 1B). Com-
pound 3 binds in a twisted conformation, as previously described for 1, with the indazole substituent
at C5 of the pyridine ring forming a pi-cation interaction with Arg356 (Figure 1B) (Mallinger et al.,
2015, 2016a). Compound 4 forms similar interactions with the hinge region and with the catalytic
Lys52 to those observed for compound 3, and its p-chlorophenyl substituent occupies the same
region as the indazole subsituent of compound 3; however, the scaffold architecture of the two com-
pounds is entirely different (Figure 1B). Throughout our studies on both chemical series, we
observed a strong correlation between the compounds’ affinities for both CDK8 and CDK19, sug-
gesting that selective inhibition of CDK8 versus CDK19 is likely to be a significant challenge
(Dale et al., 2015; Mallinger et al., 2016a). This reflects the high sequence similarity between
CDK8 and CDK19 (Figure 1C). We also tested selected compounds from a further three chemical
series that we identified from the literature and again could not detect any substantial selectivity for
CDK8 versus CDK19 (Figure 1—source data 1).
In vitro activity of chemical probes and preclinical candidates
We confirmed compound activity in a range of in vitro assays using human colorectal cancer cell
lines, including some with an increased CDK8 gene copy number (Figure 1—source data 1). All four
compounds potently inhibited a WNT-dependent reporter in all of the cell lines tested, but did not
inhibit a WNT-independent housekeeping EEF1A1 promoter-reporter construct in the negative
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Figure 1. Optimised compounds for exploring CDK8 and CDK19 function. (A) Chemical structure and activity of compounds 2, 3 and 4 (n > 2, mean ±
s.d.). (B) Overlay of 3 (grey; ocd 5HBJ) and 4 (pink; Pdb code: 5IDN) bound to CDK8/CCNC. Key interactions (yellow) and residues are shown. Residues
23 – 39 and 359 – 361 have been cropped for clarity. (C) Amino acid sequence alignment for human CDK8 and CDK19. Red, sequence differences;
yellow, ATP binding; green, CCNC binding; gray, activation loop; blue, inhibitor binding. (D) Luciferase activity in COLO205-cl4 cells containing a TCF/
LEF reporter gene construct following 24 hr compound treatment (n = 4, mean ± s.d.). (E) Colony assay. Plates were seeded with LS513 or insensitive
RKO cells and treated for 14 d.
DOI: 10.7554/eLife.20722.003
The following source data and figure supplements are available for figure 1:
Source data 1. Properties of CDK8/19 ligands and their effects on reporter expression and cell proliferation in a human colorectal cancer cell line panel.
DOI: 10.7554/eLife.20722.004
Figure supplement 1. Effect of CDK8 and CDK19 shRNA and siRNA treatment in CDK8-amplified human colorectal cancer cell lines.
DOI: 10.7554/eLife.20722.005
Figure supplement 2. Comparison of CDK8 and CDK19 gene copy number or protein expression with sensitivity to treatment with compound.
DOI: 10.7554/eLife.20722.006
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control RKO colorectal cancer cell line, which expresses low levels of beta-catenin (Figure 1D and
Figure 1—source data 1) (Mallinger et al., 2015; Dale et al., 2015). Weakly-active negative-control
compounds from the 3,4,5-trisubstituted pyridine and 3-methyl-1H-pyrazolo[3,4-b]pyridine series
(compounds 5 and 6 respectively) did not inhibit reporter gene expression or STAT1SER727 phosphor-
ylation (Figure 1—source data 1). Given the potent inhibition of reporter activity we were surprised
by the lack of effect of our potent inhibitors on tumor cell proliferation after standard 4 d continuous
exposure conditions (Figure 1—source data 1). However, this was consistent with a reported lack of
antiproliferative effects for a different chemical series in a single colorectal cancer cell line
(Koehler et al., 2016). Silencing of CDK8 and/or CDK19 by shRNA in CDK8-amplified COLO205
cells also had no effect on viability, despite evidence for inhibition of reporter output or target gene
expression (Figure 1—figure supplement 1A). Knockdown was more effective when we used CDK8
and/or CDK19 siRNA in CDK8-amplified HT29 cells, but again we saw no significant effect on viabil-
ity after 5 d exposure to siRNA, despite near complete inhibition of STAT1SER727 phosphorylation by
the CDK8 siRNA (Figure 1—figure supplement 1B–C). In contrast, a 14 d colony growth assay
revealed a significantly similar antiproliferative effect for the lead compounds from both chemical
series (p<0.001 for all comparisons with 1, 3 and 4; Figure 1—figure supplement 2), which was not
observed for the negative-control compounds 5 and 6. However, no compounds showed colony
growth inhibition in the negative control RKO colorectal cancer cell line (Mallinger et al., 2015;
Dale et al., 2015). In this assay, we found three beta-catenin mutant (LS513, LS180, LS174T) and an
APC mutant (SW620) colorectal cell lines to be most sensitive to treatment (Figure 1E and Fig-
ure 1—source data 1). The association between beta-catenin mutation and sensitivity to compound
treatment in the colony assay did not reach significance (p>0.05). The lack of response of the RKO
cells suggested that colony growth in this line did not require beta-catenin or CDK8 and contrasted
with the APC or beta-catenin mutant lines where colony growth appeared to be dependent on beta-
catenin-regulated transcription that also required CDK8/19. Overall, there was no significant correla-
tion between compound activity in TCF-reporter, phospho-biomarker, colony growth assays and
either CDK8/19 protein levels or gene copy number (Figure 1—figure supplement 2 and Figure 1—
source data 1).
CDK8/19 ligands have modest activity against human colorectal cancer
tumor xenogafts
Next, we determined if our two series of compounds had antitumor activity in vivo in human colorec-
tal cancer xenograft mouse models. Previously, we demonstrated that compound 1 inhibited TCF/
LEF-reporter gene expression and reduced STAT1SER727 phosphorylation by >80%. This translated
into tumor growth inhibition following oral dosing of 1 in mice bearing established COLO205 or
SW620 colorectal cancer cell xenografts (Mallinger et al., 2015; Dale et al., 2015). We also found
evidence for a significant, dose-dependent, reduction in tumor growth in HCT116 human colorectal
cancer cell line xenografts as well as significant tumor growth inhibition (TGI = 81%; p<0.001) at
70 mg/kg in an LS513 human colorectal cancer xenograft model with concomitant reduction of
p-STAT1SER727 at 6 hr (Figure 2—figure supplement 1 and Figure 2—source data 1).
For the lead compounds 3 and 4, we modelled the inhibition of STAT1SER727 phosphorylation
using multiple sets of experimentally-derived data from HCT116 and SW620 human tumor xeno-
grafts (Figure 2 and Figure 2—figure supplement 2A–C). Detailed analysis, initially in HCT116
tumor xenografts, showed that maximal inhibition of STAT1SER727 phosphorylation required treat-
ment with 5 mg/kg compound 3 and that higher concentrations prolonged the period of maximal
inhibition (Figure 2—figure supplement 2A–C). In SW620 tumor xenografts biomarker inhibition
was rapidly achieved following treatment with 3 or 4 and could be maintained for approximately 10
hr after a single treatment with 30 mg/kg of 3, while 30 or 100 mg/kg of 4 prolonged the period of
inhibition of STAT1SER727 phosphorylation so that, unlike 3, multiple dosing with 4 prevented recov-
ery of biomarker to control levels between treatments (Figures 2A,3D–E, Figure 2—figure supple-
ment 2D and Figure 2—figure supplement 3B). Both lead compounds 3 and 4 exhibited
reproducible, dose-dependent antitumor activity in SW620 tumor xenografts (Figure 2D–E, Fig-
ure 2—figure supplement 3A–B and Figure 2—source data 1) and also in an additional LS1034
colorectal tumor model that responded to our compounds in the in vitro clonogenic assay (Fig-
ure 2—figure supplement 3C–E, Figure 2—figure supplement 4 and Figure 2—source data 1).
While 5 mg/kg compound 3 induced maximal inhibition of STAT1SER727 phosphorylation in SW620
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human tumor xenografts, its effects were short-lived, and were not sufficient to translate into antitu-
mor activity (Figure 2—figure supplement 2D and Figure 2—source data 1). However, higher 30
mg/kg doses of compound 3 prolonged the maximal inhibition of STAT1SER727 phosphorylation and
had a significant (p<0.01) antitumor effect (Figure 2—figure supplement 3A–B and Figure 2—
source data 1). As with 3, 10 mg/kg of 4 inhibited the pathway biomarker for 6 hr, but was not suffi-
cient for antitumor activity in SW620 xenografts (Figure 2A and Figure 2—source data 1). However,
Figure 2. Target inhibition and antitumor activity of CDK8/19 ligands 3 and 4 in established human colorectal cancer cell line xenografts. (A) Level of
p-STAT1SER727 in SW620 human colorectal cancer xenografts following a single dose of 4, relative to the p-STAT1SER727 level in vehicle-treated mice.
Significance was determined by Kruskal-Wallis test and Dunn’s post-test (*p=<0.001; ). (B, C) Modelling of experimental data, including data from (A)
and Figure 2—figure supplement 2D, of STAT1SER727 phosphorylation following (B) single or (C) twice daily doses of 30 mg/kg 3 (black) or 30 and
100 mg/kg 4 (orange and purple). (D) Volume of SW620 xenografts in mice treated with 4 or a vehicle control. (E) Level of p-STAT1SER727, relative to
control, in SW620 tumor xenografts at the stated time following the final dose of 4 (from D).
DOI: 10.7554/eLife.20722.007
The following source data and figure supplements are available for figure 2:
Source data 1. Details of human colorectal cancer cell line xenograft studies.
DOI: 10.7554/eLife.20722.008
Figure supplement 1. Differential antitumor activity in human LS513 colorectal cancer xenografts treated with CDK8/19 ligand 1.
DOI: 10.7554/eLife.20722.009
Figure supplement 2. Pharmacodynamic profiling of CDK8/19 ligand 3 in human colorectal cancer xenografts.
DOI: 10.7554/eLife.20722.010
Figure supplement 3. Antitumor activity and target engagement in human colorectal cancer xenografts treated with CDK8/19 ligands 3 and 4.
DOI: 10.7554/eLife.20722.011
Figure supplement 4. LS1034 colony assay.
DOI: 10.7554/eLife.20722.012
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repeated dosing of 4 at 50 or 100 mg/kg prolonged the inhibition of STAT1SER727 phosphorylation
and gave evidence of antitumor activity (Figure 2D–E and Figure 2—source data 1). Hence, the
antitumor activity of 3 and 4 against colorectal cancer xenografts showed clear dose-dependence,
with a requirement for prolonged pathway inhibition in order to significantly reduce tumor growth.
CDK8/19 ligands have modest activity in patient-derived tumor
xenograft models
To follow up our standard xenograft experiments, we next tested compound activity in human
patient-derived tumor xenograft models (PDXs). Firstly, we determined if our compounds were
active in in vitro soft agar clonogenic assays, using cells derived from 89 distinct PDX models from
different tissue types. In this assay, colony growth was inhibited, but only by up to 50%, in one-third
of PDX cell cultures treated with tool compound 2 (Figure 3A–B). Six of the more sensitive colorec-
tal PDX tumor models were selected for in vivo monotherapy either with the lead compound 3
alone, or combined with a standard of care drug (irinotecan or oxaliplatin). Only two of these colo-
rectal cancer PDX tumors models, CFX 883 and CFX 1753, responded to monotherapy with 3
(p<0.0001; Figure 3—figure supplement 1A). Importantly, the combination of 3 with standard of
care therapies was only of statistically significant benefit in one colorectal tumor model, CFX 1034
(p<0.001; Figure 3C and Figure 3—figure supplement 1). Examination of p-STAT1SER727 levels indi-
cated near maximal CDK8 inhibition in the three tumors where p-STAT1SER727 was tested (p<0.0001;
Figure 3. In vitro and in vivo activity of CDK8/19 ligands in patient-derived tumour xenograft models. (A) GI50 values for 2 in PDX soft agar colony
cultures. (B) Exemplar dose-response profiles for selected colorectal cancer clonogenic assays treated with 2. (C) Volume of human colorectal cancer
CXF 1034 (CTNNB1MUT, PIK3CAMUT, PTENMUT) PDXs in mice treated with vehicle, 3 and / or irinotecan (mean values ± s.e.m., n = 10 per cohort). Tumor
volume was significantly different (p=<0.001; 2 way ANOVA and Tukey’s multiple comparison test) in mice receiving the combination treatment,
compared with the monotherapy groups. (D) Level of p-STAT1SER727, relative to control, in CXF 1034 xenografts in mice treated with 3 measured 1 hr
after the final dose (p=<0.0001, Mann-Whitney test; mean values ± s.d., n = 10 per cohort).
DOI: 10.7554/eLife.20722.013
The following figure supplements are available for figure 3:
Figure supplement 1. In vivo activity of CDK8/19 ligand 3 in PDXs.
DOI: 10.7554/eLife.20722.014
Figure supplement 2. Pharmacodynamic and antitumor activity of 3 and 4 in AML models.
DOI: 10.7554/eLife.20722.015
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Figure 3 and Figure 3—figure supplement 1B and D), indicating that the failure of 3 to slow PDX
growth (Figure 3—figure supplement 1C and F) was unlikely to be due to a lack of target
engagement.
The most CDK8/19 inhibitor sensitive cell model in the soft agar assays was one of the two acute
myeloid leukaemia (AML) cell lines, Nomo-1, included in the cell panel. The Nomo-1 line was particu-
larly sensitive to treatment with compound 2 (Figure 3A) with an 11 nM GI50. Subsequently, in a
Nomo-1 systemic in vivo model, treatment with 3 led to a potent reduction in circulating tumor cells
(Figure 3—figure supplement 2A–B). An additional subcutaneous MV-4-11 AML xenograft also
responded to monotherapy (TGI = 100%) with 10 mg/kg po qd 3, and also with 4 which showed evi-
dence of near maximal target inhibition, as determined using p-STAT1SER727 at 2 hr post-treatment
(Figure 3—figure supplement 2C–D).
Gene expression microarray profiling of human colorectal cancer
xenografts post-treatment
Having demonstrated target engagement and associated antitumor activity in vivo, we further
explored the molecular response of tumors treated with compounds 1 and 3 (Figure 4—source
data 1). We initially identified 278 transcription factor-associated genesets that were enriched in
genes whose expression was significantly altered following in vivo treatment of COLO205 or SW620
human tumor xenografts. The altered expression of 121/278 of these transcription factor-associated
genesets was identified following treatment of both xenografts (Figure 4A). Of note we also identi-
fied 185 transcription factor-associated genesets that were significantly enriched in sets of genes
associated with super-enhancers; of these, 2/3rds were shared with the genesets whose expression
was altered by compound treatment (Figure 4A). These common transcription factor genesets
included transcription factors known to be regulated by CDK8, such as TCF4, SMADs, STATs, c/EBP
and HIF1A (Figure 4—source data 1) (Bancerek et al., 2013; Morris et al., 2008; Zhao et al.,
2013; Fryer et al., 2004; Alarco´n et al., 2009; Zhao et al., 2012). The genesets shared between
both treatment and super-enhancers also encompassed transcription factors (NANOG, OCT3/4 and
SOX2) required for stem cell pluripotency (Figure 4—source data 1) (Whyte et al., 2013).
A similar analysis, but this time of genes encoding specific pathway components, found 85 gene-
sets were significantly enriched in the pool of genes whose expression was modulated by compound
treatment (Figure 4A); 15 of which were found in both colorectal cancer xenograft experiments. A
third of these were geneset-encoded gene products associated with WNT signaling, while others
encoded components of individual pathways involved in development, inflammation or osteoblast
biology (Figure 4—source data 1). Five of the genesets, common to both tumor models, all com-
prising WNT pathway components, were enriched with super-enhancer associated genes.
In addition, we used geneset enrichment analysis (GSEA) to compare the compound-treated pro-
files with sets of genes associated with super-enhancers identified from published ChIP-seq datasets
(Pelish et al., 2015), and genesets from MSigDB (www.broadinstitute.org/msigdb). We found that
treatment of both tumor models resulted in a consistent and significant modulation of genes in the
vicinity of MED1 and CDK8-associated super-enhancers identified from ChIP-seq datasets
(Figure 4B–C and Figure 4—source data 1). Interestingly, super-enhancers defined by a BRD4
ChIP-seq in lymphoid cells did not show the same significant modulation as the MED1/CDK8-defined
super-enhancers (Figure 4B–C). The expression of many of the MSigDB genesets were positively or
negatively correlated with the compound-treated samples and included genesets encoding gene
products associated with, or regulated by, developmental, immunological or inflammatory pathways
(Figure 4—source data 1). Some patterns were common to all treated samples, for example the
genesets with decreased expression associated with stem cell pluripotency (SOX2, NANOG and
OCT4) were modulated by treatment in both of the tumor models and also with both 1 and 3 (Fig-
ure 4—figure supplement 1). In contrast, other genesets exhibited cell line-specific regulation, for
example the expression of bone morphogenic protein 2 (BMP2)-regulated genes and others associ-
ated with bone remodelling were inhibited by treatment of COLO205 xenografts, but were activated
in SW620 xenografts (Figure 4—figure supplement 1).
Overall, the altered levels of transcripts from genes influenced by transcription factors or super-
enhancers known to be regulated by the Mediator complex and CDK8 are consistent with our com-
pounds affecting a broad range of CDK8/19-regulated gene transcription (Mallinger et al., 2015).
Clarke et al. eLife 2016;5:e20722. DOI: 10.7554/eLife.20722 8 of 25
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The genes and genesets identified suggested that effects on stem cells, bone, immunology and
inflammation might influence compound tolerability (Figure 4—figure supplement 1).
Altered cell distribution in hyperplastic intestinal crypts following
treatment
Among the profiles identified by GSEA were those associated with the regulation of normal and
tumor stem cell populations (Figure 4—source data 1). We used a mouse model expressing doxycy-
cline (Dox)-inducible activated beta-catenin (Jarde´ et al., 2013) to explore the effect of the tool
compound 1 on an oncogenically-activated stem cell compartment. We separated the crypt-cell
compartment from intestinal epithelial cells using a panel of cell surface markers (Figure 5—figure
supplement 1 and Figure 5—source data 1; Wang et al., 2013). GRP78 staining was then used to
separate stem-like and transit amplifying-like (TA) cells, the success of which was confirmed by RT-
PCR (Figure 5A and Figure 5—source data 1).
Figure 4. Microarray gene expression profiling following in vivo treatment of human colorectal cancer xenografts with CDK8/19 ligands. Mice were
treated with 70 mg/kg po 1 (SW620 and COLO205), 20 mg/kg po 3 (COLO205). (A) Venn plots of transcription factor-associated genesets or those
encoding or regulating pathways enriched in genes whose expression was significantly altered by treatment (Supplementary Dataset). (B) GSEA of
CDK8 or BRD4-associated super-enhancer genes in treated human tumor xenografts. (C) Scatterplot of false discovery rate (FDR-q) versus normalized
enrichment score (NES) for indicated gene sets evaluated by GSEA (n=10,218), signatures include those from MSigDB, dbSUPER and the ChIP-seq data
from Pelish and colleagues (Pelish et al., 2015).
DOI: 10.7554/eLife.20722.016
The following source data and figure supplement are available for figure 4:
Source data 1. Geneset expression analysis of microarray data following in vivo treatment of SW620 or COLO205 cells.
DOI: 10.7554/eLife.20722.017
Figure supplement 1. Microarray gene expression profiling following in vivo treatment of colorectal cancer cell line xenografts.
DOI: 10.7554/eLife.20722.018
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High-level induction of beta-catenin with 2 mg/mL Dox significantly increased the percentage of
stem cells (GRP78 ) in the crypt cell compartment, whereas lower-level induction with 0.1 mg/mL
Dox was associated with a larger transit amplifying (GRP78+) cell population, as previously described
(Figure 5B–C) (Hirata et al., 2013). The complete withdrawal of Dox inhibited WNT signaling in the
stem cell population, confirmed by a change in the abundance of transcripts from the WNT-regu-
lated genes Axin2 and Car4 (Figure 5D–E). However, Dox withdrawal did not significantly alter the
ratio of stem to TA cells (Figure 5B–C). In contrast, reducing the degree of Dox-induction from 2 to
0.1 mg/ml shifted the population towards an increased proportion of TA cells (Figure 5B–C). Consis-
tent with the shift from stem to TA cell distribution, the gene expression pattern in the stem cell frac-
tion was similar to Dox-removal, but was different from the TA cell population.
Figure 5. Treatment with CDK8/19 ligand 1 reduces the hyperplastic crypt stem cell population. Gene expression, measured by RT-PCR, in
the intestinal epithelial stem and TA cells isolated from mice expressing a Dox-inducible activated b-catenin transgene. (A) Transcript abundance,
relative to control, in stem and TA cells following induction with 2 mg/ml Dox. (B) Abundance of different cell types following treatment with Dox and
compound 1. (C) Proportion of stem versus TA cells following treatment. (D) Fold changes in transcript abundance in stem (D) and TA (E) cells following
treatment. All data are mean values ± s.d., n = 3.
DOI: 10.7554/eLife.20722.019
The following source data and figure supplement are available for figure 5:
Source data 1. Antibodies and PCR primers used for analysis of mouse intestinal epithelial cells.
DOI: 10.7554/eLife.20722.020
Figure supplement 1. Analysis of stem and TA cells isolated from the hyperplastic crypts of mice expressing a Dox-inducible activated b-catenin
transgene.
DOI: 10.7554/eLife.20722.021
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Previously, we demonstrated that treatment with >37.5 mg/kg compound 1 was sufficient to
inhibit WNT signaling in this model (Dale et al., 2015). Here, we found that treatment with 1 at 75
mg/kg x 3 over 24 hr resulted in a gene expression pattern in the stem cell fraction that was similar
to both Dox-removal and reduction of Dox from 2.0 to 0.1 mg/ml (Figure 5D). In contrast, the gene
expression in the TA fraction following treatment with 1 was similar to the effect of reducing the
level of Dox from 2.0 to 0.1 mg/ml, but was different from the Dox withdrawal condition
(Figure 5E). This observation was consistent with the observation that treatment with 1 resulted in a
shift in the population distribution from stem cell to TA similar to that seen by reducing the level of
Dox from 2.0 to 0.1 mg/ml (Figure 5B–C). This implies that the inhibition of CDK8/19 by 1 reduces,
rather than eliminates, WNT signaling in the oncogenically-activated stem cell compartment and it is
this that alters the proportion of stem cells to proliferative TA cells in the hyperplastic crypt.
Modulation of bone morphogenesis
GSEA also indicated that genes encoding products associated with the bone environment, such as
genes regulated by BMP2, were preferentially affected by compound treatment. Having already
determined the effect of 1 on the intestinal crypt stem cell population (Figure 5), we next investi-
gated the effect of CDK8/19 inhibition on a bone progenitor cell model. We reasoned that, poten-
tially, CDK8/19 inhibition could affect the ability of stem cells in the bone marrow to self-renew
through inhibition of the WNT pathway or via a BMP-dependent signaling mechanism that requires
SMAD-regulated transcription. SMAD is a transcriptional target of CDK8 (Alarco´n et al., 2009) and
both SMADs1-5 and BMP2-regulated gene expression were identified as significant genesets (Fig-
ure 4—source data 1).
We treated mouse KS483 osteoprogenitor cells with LGK974, a Porcupine inhibitor that inhibits
WNT signaling, and observed reduced secretion of Procollagen type I N-terminal propeptide (PINP),
an organic component of bone, and also reduced deposition of calcium, an inorganic component of
bone (Figure 6A–B) (Dang et al., 2002). In contrast, compound 3 stimulated PINP secretion at low
concentrations and inhibited PINP secretion at higher concentrations (Figure 6A), while calcium
deposition was inhibited in a concentration-dependent manner (Figure 6B). These data indicate that
our lead compound 3 adversely affects bone development in an in vitro model and that its effects
are distinct from a specific inhibitor of WNT signaling.
Modulation of immune and inflammatory response in co-culture models
Genesets associated with the immune and inflammatory response were selectively affected by our
CDK8/19 ligands, prompting us to examine the effects of our compounds on immune and inflamma-
tory responses (Figure 4—source data 1). In 12 single or co-culture in vitro tissue models we
assayed 163 clinically relevant extracellular biomarkers including cytokines, chemokines, membrane
receptors, matrix components, and proteases (Figure 6—figure supplement 1 and Figure 6—
source data 1) (Berg et al., 2010). All four compounds (1–4) elicited a similar biomarker response
across the cell line panel (median r = 0.812; range: 0.630 – 0.924), indicating that the observed
changes were the result of CDK8/19 inhibition rather than off-target effects. Comparing the effects
of our compounds with a proprietary database of >3000 approved drugs and experimental agents
failed to find any close matches (Berg et al., 2010). The levels of interleukin 17A and 17F usually rise
and fall together (Melton et al., 2013), but treatment with our compounds elicited an unusual split
response, with an increase in IL-17A and a corresponding decrease in IL-17F (BT condition:
Figure 6C, Figure 6—figure supplement 1 and Figure 6—source data 1). Overall, the pattern
observed across the biomarkers was consistent with the effects of our compounds on inflammation
(VCAM-1, sPGE2 and IL-8), immunomodulation (IL-17A, IL-17F, HLA-DR and IgG) and tissue remod-
elling (uPAR) (Figure 6C and Figure 6—source data 1). In additional studies in rats treated with 3
we measured the levels of ten plasma cytokines associated with the Th1/Th2 immune response. Of
the cytokines measured, only IL-12, a proinflammatory and proimmunestimulatory cytokine,
increased significantly (p<0.005, Figure 6D).
Adverse effects on multiple organ systems
Compounds from both chemical series were sufficiently well tolerated in mice to enable antitumor
experiments to be conducted with a dosage regimen that resulted in near-maximal inhibition of
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tumor STAT1SER727 phosphorylation, showing that CDK8/19 activity was repressed for prolonged
periods (Figure 2, Figure 2—figure supplements 1–3, Figure 3, Figure 3—figure supplement 1.
However, there was some evidence for body weight loss that sometimes necessitated short dosing
breaks (Figure 2—source data 1). Given this sporadic body weight loss in mice and our evidence
Figure 6. Effect of CDK8/19 chemical ligands on bone development and the immune response in model systems.
Mouse KS483 osteoprogenitor cells were treated with LGK974 (red) or compound 3 (black) for 13 d and bone
matrix formation determined by measuring (A) N-terminal propeptide of type I procollagen (PINP) and (B) calcium,
in the external medium (mean ± s.d., n = 6). Blue region, level following 50 ng/ml BMP-2 (positive control); red
region, basal level. (C) Heat map showing the 10 biomarkers most affected by compound treatment in cell co-
culture models. Data are log2 ratios of biomarker levels following compound treatment relative to control (range:
 0.874 to 0.396). Blue, decreased ratio; red, increased ratio. (D) Plasma IL-12 levels in Wistar rats treated with 5 –
20 mg/kg po qd 3. Two rats per cohort.
DOI: 10.7554/eLife.20722.022
The following source data and figure supplement are available for figure 6:
Source data 1. Culture conditions and data from CDK8/19 ligand profiling in the culture/co-culture cell model panel.
DOI: 10.7554/eLife.20722.023
Figure supplement 1. Effect of CDK8/19 ligands 1-4 on 12 culture/coculture cell models.
DOI: 10.7554/eLife.20722.024
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that the compounds had effects on bone development, altered immune/inflammatory profiles and
stem cell differentiation in vitro or in vivo experimental models, we carried out detailed toleration
studies. Our aim was to determine if there was a therapeutic window for the compounds, using PK/
PD and efficacy data determined in our mouse models as a guide. Following daily doses of com-
pound 3 or 4 for 14 days in rats we detected significant, adverse alterations in multiple organ sys-
tems and tissues (Table 1). In these toleration studies, we demonstrated extensive (80%) inhibition
of STAT1SER727 phosphorylation 6 hr post-treatment at all doses of 3 tested (Figure 7—figure sup-
plement 1). The lowest doses administered resulted in plasma concentrations below or equivalent
to the plasma exposures achieved at efficacious doses in our experimental human tumor xenograft
efficacy models, suggesting the lack of a clear therapeutic window (Table 1). Consistent with our in
vitro observations of the effects on bone maturation, the rat studies revealed two different, paradox-
ical effects on bone: an inhibitory effect resulting in dysplasia of the growth plate, a decrease in the
proliferative zone and false endochondral ossification, and an activating effect resulting in prolifera-
tion of irregular woven bone in the bone cavity and below the periosteum (Table 1 and Figure 7).
Other adverse pathomorphological findings included necrotic and apoptotic cell lesions in the exo-
crine pancreas, gastrointestinal mucosa (stomach and duodenum), male reproductive tract (Figure 7),
mammary gland, skin (hair follicle), heart (valvular interstitial cells) and lymphatic tissues (thymus,
spleen, lymph nodes). Proliferative lesions were found in the lungs (bronchiolar epithelium and
smooth muscle cells), liver (bile ducts and smooth muscle cells of hepatic arteries), thymus (epithe-
lium free areas), mammary gland, male reproductive system and heart (valvular interstitial cells)
(Table 1).
Follow-up studies in dogs indicated a similar, widespread adverse safety profile at therapeutically
relevant exposures of 3 and 4 (Table 1). Since these pathological effects were seen with two highly
Table 1. CDK8/19 ligands 3 and 4 adversely affect multiple organs in rats and dogs.
Wistar rats (5 male and 5 female per cohort) or Beagle dogs (2 male and 2 female per cohort for 3 and 1 male and 1 female for 4)
received a daily oral dose of 3 or 4 for 14 days. In the rat study of 4, all animals were prematurely culled at 60 mg/kg and one male
and female at 20 mg/kg, as a result of compound toxicity. In the dog studies, all animals were prematurely culled in the study of 3 and
one female following exposure to 4 as a result of toxicity. The most severely affected organs are indicated in bold. The fold efficacious
dose was calculated from a plasma PK measurement of compound exposure in satellite animals run in parallel to the tolerability study
and compared to exposures at efficacious doses in human tumour xenograft models in mice (m – male and f – female).
Rat Dog
Low dose Mid dose High dose Low dose
CMPD 3
(mg/kg)
5 10 20 5
Target
organs
Bone, bone, marrow, heart, liver, lung,
lymph nodes, pancreas, reproductive
tract (m), spleen, thymus.
Bone, bone marrow, heart, liver, lung,
lymph nodes, pancreas, reproductive
tract (m and f), spleen, thymus.
Bone, bone marrow, heart, liver, lung,
lymph nodes, pancreas, reproductive
tract (m and f), spleen, thymus.
Bone marrow,
gastrointestinal
mucosa,
heart, lymphatic
system
Fold of
efficacious
dose;
10 mg/kg
~0.3 (m) – 1.3 (f) ~0.5 (m) – 2 (f) ~1 (m) – 5 (f) ~0.3 (m) – 0.3 (f)
CMPD 4
(mg/kg)
10 20 60 20
Target
organs
Bone, bone marrow, intestines, liver,
lung, lymph nodes, mammary gland,
pancreas, reproductive tract (m and f),
skin, spleen, stomach, thymus.
Bone, bone marrow, heart, intestines,
liver, lung, lymph nodes, mammary
gland, pancreas, reproductive tract (m
and f), skin, spleen, stomach, thymus
Bone, bone marrow, brain, heart,
intestines, liver, lung, lymph nodes,
mammary gland, pancreas,
reproductive tract (m and f), skin,
spleen, stomach, thymus
Bone marrow,
heart,
Intestines,
lymphatic
system
Fold of
efficacious
dose;
10 mg/kg
30 mg/kg
~0.9 (m) – 2.4 (f)
~0.3 (m) – 0.8 (f)
~3.9 (m) – 5.7 (f)
~1.3 (m) – 1.9 (f)
~10.8 (m) – 23.1 (f)
~3.6 (m) – 7.7 (f)
~22 (m) – 46 (f)
~7 (m) – 15 (f)
DOI: 10.7554/eLife.20722.027
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selective, but structurally distinct CDK8/19 inhibitors in both rats and dogs, we conclude that the
adverse effects of treatment are the direct result of inhibition of CDK8 and/or CDK19. These obser-
vations indicate that the clinical development of either series of CDK8/19 inhibitors, or other chemo-
types with similar profiles, would be extremely challenging.
Discussion
CDK8 may reportedly act both as an oncogene and as a tumor suppressor, but until recently, the
absence of a potent and selective inhibitor of CDK8 has restricted many functional studies to genetic
inhibition using shRNA or siRNA (Mitra et al., 2006; Chattopadhyay et al., 2010; Gu et al., 2013;
Firestein et al., 2008, 2010; Seo et al., 2010; Adler et al., 2012; Starr et al., 2009). The potential
difference between loss of protein and inhibition of enzymatic activity is highlighted by a recent
study with the natural product CDK8/19 inhibitor cortistatin A that found a treatment-induced gene
expression profile distinct from the profile resulting from CDK8/19 shRNA knockouts in the same
cell line (Poss et al., 2016). Also conscious of the potentially opposing context-dependent roles of
CDK8 in tumor development, we set out to clarify the therapeutic potential of targeting CDK8/19.
Using two structurally-distinct series of potent and highly selective ligands that we discovered, we
explored the consequences of CDK8/19 targeting in vitro and in vivo and investigated tolerability to
determine if there was a therapeutic window (Mallinger et al., 2015, 2016a; Czodrowski et al.,
Figure 7. Examples of degenerative and proliferative lesions in rats treated with CDK8/19 ligands 3 or 4. (A) Intact proliferative zone in the bone growth
plate of a control rat. (B) Dysplastic proliferative zone, showing disturbance of regular endochondrial ossification, from a rat treated with 20 mg/kg 3.
Scale bar in A and B = 100 mm. (C) Intact epididymides, with epididymal cells, isolated from a control rat. (D) Epididymides with epithelial hyperplasia
(distal corpus) isolated from a rat treated with 60 mg/kg 4. Scale bar in C and D = 50 mm.
DOI: 10.7554/eLife.20722.025
The following figure supplement is available for figure 7:
Figure supplement 1. Pharmacodynamic response in Wistar rats treated with CDK8/19 ligand 3.
DOI: 10.7554/eLife.20722.026
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2016). Despite reproducible inhibition of TCF/LEF reporter activity and STAT1SER727 phosphorylation
by both series of compounds, we were only able to detect modest, though generally significant,
antiproliferative or antitumor effects in vitro or in vivo. In follow-up studies on cell cultures derived
from PDX tumors, and selected PDXs in vivo, we found that compounds from the 3,4,5-trisubstituted
pyridine series had only modest effects in vitro and little effect in vivo despite maximal inhibition of
STAT1SER727 phosphorylation. The pleiotropic nature of CDK8/19 function, influencing the activity of
multiple specific transcription factors and also super-enhancers, may make identification of bio-
markers for particular cancer cell types that are especially sensitive to CDK8/19 inhibitors challeng-
ing; despite this both series of compounds did show greater potency in a systemic or subcutaneous
model of human AML, similar to that reported for the natural product inhibitor of CDK8/19, cortista-
tin A (Pelish et al., 2015).
We found that the in vivo activity of our CDK8/19 inhibitory compounds was associated with
modulation of gene expression regulated by transcription factors that are CDK8 substrates. More-
over, Pelish and colleagues (Pelish et al., 2015) recently demonstrated that in AML cells CDK8 is
associated with gene super-enhancers and that pharmacological inhibition of CDK8 activated super-
enhancer output. Here, we also found that pharmacological inhibition of CDK8 with our potent and
selective chemical probes in colorectal cancer models resulted in gene expression profiles consistent
with increased super-enhancer activity. Genes whose expression were altered by the compounds
included those encoding products associated with bone development, stem cell biology, immunol-
ogy and inflammation. Extensive follow up experiments in in vitro and in vivo models demonstrated
effects on bone, stem cell differentiation and response of immune cells to different stimuli. Some of
the effects were unique, for example concentration-dependent stimulation or inhibition of bone
matrix production by osteoprogenitor cells in vitro that was not observed with a WNT-pathway
inhibitor.
CDK8 activity maintains embryonic stem cells in an undifferentiated, pluripotent state and colo-
rectal tumors in a de-differentiated state (Adler et al., 2012). We found that complete inhibition of
CDK8/19 in the presence of activated oncogenic beta-catenin mimicked the effect of reducing,
rather than completely abrogating, WNT-signaling. CDK8/19 inhibition resulted in a shift from a
stem cell to a predominantly TA cell phenotype. This response may also be linked to super-enhancer
activation, as expression of Myc, a super-enhancer-regulated gene (Love´n et al., 2013), was
repressed in the stem cell population, but elevated in the TA cell population following compound
treatment. The example of Myc illustrates the potential complexity of the response to CDK8 inhibi-
tion, as Myc expression will potentially be repressed through loss of CDK8 activity required by beta-
catenin, but Myc expression may also be promoted through super-enhancer activation. This suggests
that cellular context will have a major impact on the transcriptional response to CDK8 inhibition.
The final key aim of our studies was to investigate tolerability to CDK8/19 inhibition and identify a
possible potential therapeutic window for compounds 3 and 4. In rat and dog tolerability studies,
we found that 3 and 4 produced unusually extensive, but similar, adverse effects in a wide range of
tissues. Given our observations, that are consistent with the reported role of CDK8 in repressing
super-enhancer activity (Pelish et al., 2015), and the potentially key roles of super-enhancers as mas-
ter controllers of cell identity and function (Whyte et al., 2013), the breadth, degree and depth of
adverse effects is perhaps not surprising. We detected elevation of the mainly proinflammatory and
proimmunestimulatory associated cytokine, IL-12, in rats treated with 3. Elevated IL-12 may result
from decreased STAT1SER727 following CDK8 inhibition, as bone marrow macrophages from
STAT1S727A mutant mice exhibit elevated IL-12 and Cox-2 expression following activation
(Schroder et al., 2007). Cox-2 induction is associated with an increased production of PGE2, which
we detected in vitro, that may also explain the unusual split response of increased IL-17A and
decreased IL-17F observed in our in vitro experiments, since PGE2, or agonists of the EP receptor
for PGE2 are among the few stimuli that induce this split effect (Melton et al., 2013).
We concluded that the multiplicity of preclinical pathomorphological lesions would make moni-
toring and controlling toxicity in a clinical study very challenging, especially as no clear safety win-
dow could be established from our studies. Our data strongly suggest that the adverse effects are
target related as they are detected with two chemically distinct series of potent and selective CDK8/
19 ligands and indicate that dual pharmacological CDK8/19 inhibition is not tolerated in rats or dogs
at exposure levels that correspond to therapeutically relevant exposures. Even in the more sensitive
xenograft models of AML, there was no clear therapeutic window, as these tumors responded only
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when STAT1SER727 phosphorylation was continuously inhibited and equivalent exposures were not
tolerated in our in vivo rat and dog toleration studies. Protein kinase inhibitors in clinical develop-
ment or approved often have off-target activity or in some cases can be intentionally multi-targeted
to have inhibitory activity against multiple protein kinases. Our observations are important for both
scenarios as we identify CDK8/19 as potential ‘anti-targets’ to be avoided and we recommend
screening against these protein kinases when establishing the safety profile of lead compounds and
development candidates as well as assessing the quality of chemical probes.
As described earlier, the natural product cortistatin A was recently reported by Pelish and col-
leagues as a CDK8/19 inhibitor with specificity, potency, favourable pharmacokinetics that would
make it a useful in vitro and in vivo probe for the Mediator kinases and as a promising lead for devel-
opment of therapeutics (Pelish et al., 2015). Here, we employed two different series of potent and
selective CDK8/19 inhibitors, with paired negative controls, that are much less challenging to synthe-
sise compared to cortistatin A (Pelish et al., 2015). Our synthetic compounds have optimal pharma-
cological and pharmaceutical properties with single digit nM affinities for CDK8/19 and low
nanomolar activity against promoter and STAT1SER727 reporter assays and are as potent as cortistatin
A, as well as exhibiting very high selectivity in broad kinome profiling. As described by Pelish and
colleagues for cortistatin A, we found similar induction of super-enhancer-regulated genes with our
compounds, although note that in our case we profiled gene expression in tumours treated in vivo
rather than in vitro (Pelish et al., 2015). Similar to cortistatin A our compounds were also tolerated
in mice and likewise we also found AMLs to be highly sensitive in vivo models (Pelish et al., 2015).
However, in our study we also evaluated our two series in dedicated tolerability studies in rat and
dog that revealed toxicity not apparent in mouse studies. The detailed toxicity profile of cortistatin
A was not reported by Pelish and colleagues, but given the similarities in the results from in vitro
and in vivo studies between cortistatin A and our two series we predict that cortistatin A and other
CDK8/19 inhibitors would exhibit similar toxicity.
It remains to be seen if toxicity could be avoided if CDK8/19 inhibitors were administered inter-
mittently as part of a combination therapy. For example, CDK8/19 inhibitors might modulate antitu-
mor immunotherapy by inactivating STAT1 and stimulating tumor surveillance by NK cells
(Putz et al., 2013). It is also unclear if toxicity could be avoided by selectively targeting CDK8 or
CDK19 alone. During the optimisation of both the 3,4,5-trisubstituted pyridine and 3-methyl-1H-pyr-
azolo[3,4-b]pyridine series, we were unable to separate CDK8 from CDK19 affinity (Mallinger et al.,
2015, 2016a; Czodrowski et al., 2016). This is also true for two additional distinct chemical series
that we identified (Schiemann et al., 2016; Mallinger et al., 2016b), and also for a further three
chemotypes we profiled from the literature, all of which demonstrated balanced CDK8 and CDK19
affinity in our hands. Similarly, the natural product cortistatin A cannot selectively distinguish
between CDK8 and 19 (Pelish et al., 2015). The inability to selectively target CDK8 or CDK19 is
likely due to the very high degree of sequence similarity around the active site of these two kinases
(Figure 1c), suggesting that strategies to selectively target either of these paralogs will require a dif-
ferent approach, such as allosteric modulation or selective degradation.
The recent identification of selective inhibitors of the transcriptional kinases CDK7 or CDK12/13
has fuelled interest in the clinical development of inhibitors of these targets (Kwiatkowski et al.,
2014; Wang et al., 2015; Zhang et al., 2016; Christensen et al., 2014; Chipumuro et al., 2014).
This is of relevance here as inhibition of these kinases has also been reported to affect super-
enhancer-associated gene expression in T cell acute lymphoblastic leukaemia, B cell chronic lympho-
cytic leukaemia, MYCN-driven tumours, small cell lung cancer and triple negative breast cancer mod-
els where anti-tumour activity is observed (Kwiatkowski et al., 2014; Wang et al., 2015;
Zhang et al., 2016; Christensen et al., 2014; Chipumuro et al., 2014). In adult CDK7 conditional
knockout mice, effects were seen in tissues with a high cell turnover that were at least in part due to
a depleted stem cell population resulting from a loss of CDK1 and CDK2 activation or reduced
super-enhancer-associated gene expression (Ganuza et al., 2012). Super-enhancers are frequently
found associated with genes whose products control the pluripotent state or define cell identity and
this may make stem cell populations particularly vulnerable to therapeutic interventions that interfere
with super-enhancer associated gene expression, including inhibitors of the transcription-regulating
CDKs (Whyte et al., 2013). In an in vivo mouse model of an oncogenically-activated stem cell com-
partment we found our CDK8/19 inhibitors altered the proportion of stem cells to proliferative TA
cells that may in part be due to super-enhancer activation. This raises the hypothetical possibility
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that, similar to AML cells (Pelish et al., 2015), the stem cell compartment requires a precise ‘dosage’
of super-enhancer activity and that activation or inhibition of super-enhancer activity will negatively
impact the stem cell compartment. The selective CDK7 tool inhibitors are reported to be tolerated
in mice and so predicted to be non-toxic (Kwiatkowski et al., 2014; Wang et al., 2015;
Christensen et al., 2014; Chipumuro et al., 2014); however, our CDK8/19 inhibitors were also toler-
ated in mice and the toxicity was not revealed until detailed tolerability studies were performed in
other species. Thus the true toxicity profile of other transcriptional CDK inhibitors may not be
revealed until dedicated tolerability studies are performed using selective compounds with opti-
mised pharmaceutical properties.
In summary, we have discovered and made available two chemically distinct series of potent
selective chemical probes and appropriate inactive control compounds that can be used to further
explore the function of Mediator-associated kinases CDK8/19 and their role in human disease both
in vitro and in vivo. These compounds will also be of particular value for exploring the regulation of
super-enhancer activity in development and disease. However, on the basis of the complex toxico-
logical profile and an inability to define a clear therapeutic window, we have decided against the fur-
ther clinical development of our compounds and suggest caution when considering the clinical
applicability of other CDK8/19 inhibitors. We also advise incorporating the profiling CDK8/19 as
anti-targets in drug discovery and chemical probe projects aimed at other kinases.
Materials and methods
Compounds
Compounds were prepared as described (Mallinger et al., 2015, 2016a; Czodrowski et al., 2016)
or resynthesised by published routes.
Biochemical assays
In vitro binding of compounds to CDK8 was determined using FRET-based Lanthascreen binding
competition with a dye-labeled ATP competitive tracer assay. Alternatively, we used a reporter dis-
placement assay provided by Proteros Biostructures GmbH (Germany) for CDK8 or CDK19 as
described previously (Mallinger et al., 2016a). The human CDK8–CCNC complex was expressed,
purified and crystallized as described previously (Dale et al., 2015). Crystals were back-soaked for
different times and concentrations of ligand before being selected for structure determination
(Dale et al., 2015).
Cell culture
Only authenticated and mycoplasma-free cell lines were used in this study. All cancer cell lines used
in this study (COLO205 - RRID:CVCL_0218; DLD1 - RRID:CVCL_0248; HT29 - RRID:CVCL_0320;
LS174T - RRID:CVCL_1384; LS180 - RRID:CVCL_0397; LS513 - RRID:CVCL_1386; RKO - RRID:CVCL_
0504; SW620 - RRID:CVCL_0547; SW837 - RRID:CVCL_1729; SW948 - RRID:CVCL_0632) were
obtained from the ATCC (LGC Promochem, UK), were regularly tested and confirmed as myco-
plasma-free (Lonza, UK) and were authenticated by short tandem repeat (STR) analysis profiling.
Multiplex amplification of genomic loci Penta E, D18S51, D21S11, TH01, D3S1358, FGA, TPOX,
D8S1179, vWA, Amelogenin, Penta D, CSF1PO, D16S539, D7S820, D13S317, and D5S818 is per-
formed using a PowerPlex 16 HS (Promega, Madison, Wisconsin, USA). STR sequences were ana-
lyzed on an Applied Biosystems 3500xL Genetic Analyzer (Thermo Fisher Scientific Life
Technologies, UK) and compared to different cell line reference databases. Soft agar PDX cell cul-
tures were run at Oncotest (Germany). Cell lines transduced with a TCF/LEF fLUC reporter were gen-
erated and assayed as described previously (Mallinger et al., 2015; Dale et al., 2015). Inducible
shRNA knockout models were established in the Colo205-F1921 subline carrying the TCF/LEF fLUC
reporter have been described previously (Dale et al., 2015).
HT29 cells (5  104/ml) were reverse transfected in 6 well plates with 3.75 ml/ml LipofectamineR-
NAiMAX (ThermoFisher Scientific, UK) in a 2 ml final volume with 50 nM pooled siRNA targeting
CDK8, CDK19 or a non-silencing control siRNA (Quiagen cat. GS1024, GS23097 and 1027280
respectively). Viability was determined by resazurin staining (R&D systems, UK) for 30 min 5 d post-
transfection.
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Bone culture assays
Bone formation assays were conducted by Pharmatest (Finland) in mouse KS483 osteoprogenitor
cells cultured for 13 d with LGK974 or 3. The amount of PINP secreted into the culture medium, and
calcium deposition, were measured by ELISA (Roche Diagnostics, UK).
In vitro coculture studies
Seven different primary cells types were exposed to different stimuli as single or co-cultures and the
response of relevant extracellular biomarkers assayed. Biomarker assays were run at DiscoveRx (Fre-
mont, California, USA) (Figure 6—source data 1). Cultures were treated with DMSO (vehicle) or a
dilution series of 1 – 10000 nM of test compounds. Profiles were compared to a proprietary data-
base of compounds previously profiled in this system (Berg et al., 2010).
Animal studies
In the UK, all animal work was conducted in accordance with the National Institute for Cancer
Research guidelines (Workman et al., 2010), with the research programme and procedures
approved by the local Animal Welfare and Ethical Review Boards and subject to UK Government
Home Office regulations (Licence PPL 70/7635 & PPL 30/3279). In Germany the animal work was car-
ried out in accordance with the German Law on the Protection of Animals (Article 8a) and the per-
taining files at the local animal welfare authorities in Darmstadt and Freiburg bear the references
DA/375, DA4/1003, DA4/1004 and G13/13 respectively. The studies were designed in accordance
with presently valid international study guidelines (e.g. ICH guideline M3 R2) and performed in com-
pliance with animal health and welfare guidelines.
Tumor xenograft studies
The establishment and treatment of cell line xenografts was performed as described previously
(Mallinger et al., 2015; Dale et al., 2015; Mallinger et al., 2016a). PDX experiments were con-
ducted at Oncotest (Germany).
Pharmacokinetic and tolerability studies
In vitro intrinsic clearance was calculated from the rate of the compound disappearance using
mouse, rat or human microsomes. The apparent permeability coefficients were calculated for com-
pounds using Caco-2 monolayers seeded on polycarbonate filters as described previously
(Mallinger et al., 2015, 2016a).
In vivo live phase PK of compounds was determined in female NMRI mice, male Wistar rats or
female beagle dogs receiving the compound either as a single intravenous (bolus) injection or an
oral administration (by gavage) of the compound. The concentrations of compound were quantified
using an UPLC method with tandem mass spectrometric detection (Mallinger et al., 2015, 2016a).
The tolerability studies were designed to meet national and international regulatory requirements
for the conduct of short-term studies in animals. In brief, Wistar rats or beagle dogs were treated
with a daily oral dose of the vehicle or compound for 14 days. Animals were culled 24 hr after the
last dose. Additional satellite animals for toxicokinetic evaluations were included. Investigations
included, but were not limited to: clinical signs, mortality, body weight, clinical pathology, cytokine
measurements and histopathology.
The ICR does not use non-rodent species in research and, where this is deemed essential,
requires ethical approval for use by organizations with whom we collaborate. Pharmacokinetic and
tolerability analysis of compounds 3 and 4 in dogs, necessary for prediction of human pharmacoki-
netics, was approved by the ICR Animal Welfare and Ethical Review Board. Studies were sponsored
and conducted in full compliance with national regulations at an Association for Assessment and
Accreditation of Laboratory Animal Care accredited site of Merck Biopharma.
In vivo stem cell analysis
Crypt structures were isolated from inducible Tet-O-b-catenin mice following treatment regimes
described in Figure 5—figure supplement 1 (Jarde´ et al., 2013). Mice were orally gavaged with 75
mg/kg 1  3 over 24 hr and doxycycline in drinking water supplemented with an i.p. dose of 0.1
mg/ml or 2.0 mg/ml doxycycline in PBS at time of gavage to maintain levels. Isolated crypts were
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dissociated into single cells, then resuspended in staining medium containing DAPI and the antibod-
ies shown in Figure 5—source data 1. Cells were sorted into lysis buffer, and gene expression
determined by RT-PCR using the primers shown in Figure 5—source data 1
Gene expression microarray profiling
Total RNA was extracted from xenograft tumors using a MagNa Pure 96 high-throughput robotic
workstation (Roche Diagnostics, UK) and analyzed by microarray expression profiling (Dale et al.,
2015). Purified, labeled cDNA products were hybridized to 8  60K human microarrays (Agilent)
and analyzed using Genespring (Agilent Santa Clara, California, USA, RRID:SCR_009196). Signifi-
cantly differentially expressed genes were investigated for enrichment in terms of particular path-
ways or potential transcription factor regulation using the Metacore software (Thomson Reuters,
New York City, New York, USA, RRID:SCR_008125). Lists of super-enhancer-associated genes were
derived from published ChIP-seq datasets (dbSUPER; http://bioinfo.au.tsinghua.edu.cn/dbsuper/
and Pelish et al., 2015). GSEA was performed on the super-enhancer gene lists and also genesets
from MSigDB (www.broadinstitute.org/msigdb). The links for the signatures used for the GSEA soft-
ware are available in the Datasets section. Users are required to register to view the MSigDB gene
sets and/or download the GSEA software. Microarray data are available on the NCBI Gene Expres-
sion Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/) website under accession number
GSE80472.
Measurement of CDK8, CDK19, p-STAT1SER737 and total-STAT1 protein
Levels of p-STAT1SER727 and total STAT1 were quantified from cell or tumor lysates by immunoblot-
ting, luminex or electrochemiluminescent ELISA as previously described in detail in (Mallinger et al.,
2015; Dale et al., 2015; Mallinger et al., 2016a; Czodrowski et al., 2016). Proteins were also
detected using an automated capillary immunoassay system (Protein Simple) with antibodies specific
for CDK8 (Cell Signaling, Danvers Massachusetts, USA #4106, RRID:AB_1903936), CDK19 (Sigma-
Aldrich, UK, HPA007053, RRID:AB_1233803) phospho-STAT1SER727 (Cell Signaling, #8826), total
STAT1 (Santa-Cruz Biotechnology, Dallas, Texas, USA, #346, RRID:AB_632435), and B-actin (Cell Sig-
nalling, #4970, RRID:AB_2223172), subsequently immunodetected using a horseradish peroxidase
(HRP)-conjugated secondary antibody and chemiluminescent substrate.
Cytokine measurement
Lithium-heparin-plasma (120 mL) was taken from each non-fasted animal on day 1 pre-dose and on
days 3 and 14 pre-dose and also 2 hr after the last treatment. The rat Th1/Th2 multiPlex bead immu-
noassay panel (Invitrogen) was used to generate calibration curves and to measure cytokine (IL-1a,
IL-1b, IL-2, IL-4, IL-6, IL-10, IL-12, IFNg, gmCSF and TNFa) levels (Luminex, Austin, Texas, USA).
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